An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.

But the timeline for a US green light is less clear, and the group has a cash crisis.

First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.

Two masked bispecific antibodies, licensed for $100m, produce promising early data.

Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.

Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.

The private group taps DualityBio for an EGFR x HER3 ADC.

The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.